There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > ErbB4


ErbB4 Molecule Information

Name:Receptor protein-tyrosine kinase erbB-4
Target Synonym:Proto-oncogene-like protein c-ErbB-4;E4ICD;ERBB4 intracellular domain;Receptor tyrosine-protein kinase erbB-4;p180erbB4;HER4;s80HER4;Tyrosine kinase-type cell surface receptor HER4;ERBB4;4ICD
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:11
Lastest Research Phase:Approved

ErbB4 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
ER4-H5251 Human Human ErbB4 / Her4 Protein, Fc Tag
ER4-H5221 Human Human ErbB4 / Her4 Protein, His Tag

ErbB4 Molecule Synonym Name


ErbB4 Molecule Background

Receptor tyrosine-protein kinase erbB-4 (ErbB4), also known as Her4, is a single-pass type I transmembrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. ErbB4 is expressed in normal skeletal muscle, heart, pituitary, brain and several breast carcinomas. ERBB4 contains multiple furin-like cysteine rich domains, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins-2 and -3, heparin-binding EGF-like growth factor and betacellulin. Ligand binding induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. ErbB4 appears to play important roles in neuronal development, development of the heart and cancer. ERBB4 has been shown to interact with: DLG4, NRG1, STAT5A, and YAP1. Mutations in this gene have been associated with cancer. Other single-nucleotide polymorphisms and a risk haplotype have been linked to schizophrenia.

ErbB4 References

ErbB4 Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Afatinib Dimaleate BIBW-2992; BIBW-2992-MA2,BIBW 2992,BIBW2992 Approved Boehringer Ingelheim GILOTRIF fda Non small cell lung cancer (NSCLC), Metastatic squamous non-small cell lung cancer (NSCLC) BOEHRINGER INGELHEIM 2013-07-12 Non small cell lung cancer (NSCLC), Metastatic squamous non-small cell lung cancer (NSCLC) Details
Neratinib Maleate CAN-030; HKI-272; PB-272; PF-0528767; WAY-179272 Approved Pfizer, Puma Biotechnology, CANbridge Life Sciences NERLYNX fda HER2-positive metastatic breast cancer PUMA BIOTECH 2017-07-17 HER2-positive metastatic breast cancer Details
Dacomitinib PF-00299804; PF-299; PF-299804; PF-804; PF-00299804-03; PF-00299804-3,PF00299804,PF299804,PF299 Approved Pfizer, SFJ pharmaceuticals VIZIMPRO fda Non small cell lung cancer (NSCLC) PFIZER INC 2018-09-27 Non small cell lung cancer (NSCLC) Details
Pyrotinib Maleate SHR-1258; BLTN; HTI-1001 Approved Jiangsu Hengrui Medicine Pyrotinib Maleate Tablets cfda HER2-positive metastatic breast cancer 2018-08-12 HER2-positive metastatic breast cancer Details

ErbB4 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Pirotinib Hydrochloride KBP-5209,KBP5209 Phase Ⅱ XuanZhu Pharma Non small cell lung cancer (NSCLC), Breast cancer, Lung cancer Details
Allitinib Tosylate AST-6; ALS-1306; AST-1306 Phase Ⅱ Shanghai Allist Pharmaceuticals Breast cancer, Lung cancer Details
AC-480 AC-480; BMS-599626 ,AC480; BMS599626 ,AC 480; BMS 599626 Phase Ⅰ Ambit biosciences Glioma, Solid tumours Details
Recombinant human neuregulin-1 rhNRG-1 BLA Filing Zensun, SciClone Chronic heart failure Details
Larotinib Mesylate Z-650 Phase Ⅱ HEC Pharm Esophagus cancer Details
BMS-690514 BMS-690514,BMS690514 Phase Ⅱ Bristol-Myers Squibb Non small cell lung cancer (NSCLC), Breast cancer Details
Tesevatinib EXEL-7647; KD-019; KD-020; XL-647,KD019,EXEL7647,KD020,XL647 Phase Ⅲ Exelixis, Kadmon Non small cell lung cancer (NSCLC), Autosomal dominant polycystic kidney disease (ADPKD) Details
PB-357 PB-357 Phase Ⅰ Pfizer Solid tumours Details
Sirotinib Maleate XZP-5491,XZP5491 Phase Ⅰ XuanZhu Pharma Esophageal squamous cell carcinoma, Non small cell lung cancer (NSCLC), Gastric cancer Details
Tarloxotinib Bromide TH-4000; PR-610; SN-33999 Phase Ⅱ Threshold Non small cell lung cancer (NSCLC) Details
Poziotinib HM-78136; HM-78136B; NOV1201; NOV-120101 Phase Ⅱ Hanmi, Luye Pharma, Spectrum Pharmaceuticals Non small cell lung cancer (NSCLC), Gastric cancer, Breast cancer, Lung cancer, Head and neck cancer Details

This web search service is supported by Google Inc.